A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-017-0429-3
Abstract: Background Infusion-related reactions (IRRs) are a major adverse event of rituximab. Objective To develop a prediction model for IRRs to rituximab among patients with B cell non- Hodgkin’s lymphomas (B-NHL). Setting A 1000-bed university hospital… read more here.
Keywords: irrs rituximab; rituximab; infusion related; prediction model ... See more keywords
Risk factors for infusion-related reactions following Ocrelizumab infusion in a community setting: Development of an electronic medical record-based explanatory model.
Sign Up to like & getrecommendations! Published in 2020 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2020.102700
Abstract: BACKGROUND In 2017, ocrelizumab became the first FDA approved disease modifying therapy (DMT) for primary progressive multiple sclerosis (MS). Although effective, adverse infusion-related reactions (IRR), such as erythema, pruritus, hives, and throat irritation, were frequently… read more here.
Keywords: explanatory model; development; infusion related; related reactions ... See more keywords
The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21197213
Abstract: Fabry disease (FD) is an X-linked lysosomal disorder caused by mutations in GLA gene resulting in lack of or faulty α-galactosidase A (α-GalA) enzyme. Enzyme replacement therapy (ERT) with recombinant human α-GalA enzyme (agalsidase) is… read more here.
Keywords: mast; fabry disease; infusion related; mast cell ... See more keywords